Adenosine vs Diltiazem for Treatment of SVT in the ED
Phase 4
Not yet recruiting
- Conditions
- Supraventricular Tachycardia (SVT)
- Interventions
- Registration Number
- NCT06993038
- Lead Sponsor
- Anne E. Zepeski
- Brief Summary
This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Adult patients (18 years and older)
- Diagnosis of acute, stable SVT in the emergency department
Exclusion Criteria
- Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
- Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
- History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)
- Severe bronchoconstrictive lung disease
- Prior hypersensitivity to study medication
- Previously enrolled in pilot study
- Pregnant
- Incarcerated
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Adenosine adenosine - Diltiazem diltiazem -
- Primary Outcome Measures
Name Time Method Feasibility outcome From enrollment to the end of ED encounter (up to 24 hours). Participants who complete all study procedures (Threshold \>80%)
- Secondary Outcome Measures
Name Time Method